Reska Biotech Inc

Reska Biotech Inc maintains a strong liquidity position with a current ratio of 0.86, indicating that its current liabilities slightly exceed its current assets. The company has no long-term debt, and its debt-to-equity ratio is 0.0, reflecting a debt-free capital structure. The company's operating cash flow of $2,325,190 supports its liquidity, although its cash and equivalents are relatively low at $13,540. In terms of profitability, Reska Biotech Inc demonstrates a return on equity of 17.76%, which is a strong indicator of efficient use of shareholders' equity to generate profits. The company's operating income of $1,085,600 and net income of $889,400 suggest a healthy margin, although specific comparisons to industry medians are not available in the provided data. The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. Geographically, the company's exposure is not detailed, but the absence of segmental or geographic diversification may pose concentration risks. Reska Biotech Inc's growth trajectory is not explicitly outlined in the available data, but the company's operating cash flow and net income suggest a stable financial performance. The absence of capital expenditures indicates that the company is not currently investing in new projects or expansions. The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The absence of long-term debt and the presence of positive operating cash flow contribute to a low liquidity risk profile. The company's dilution risk is also low, as there are no signs of imminent share issuance or dilution pressures. Recent events and filings do not show any significant developments for Reska Biotech Inc. The company's financial statements and risk assessment do not indicate any material changes or events that would impact its operations or financial position in the near term.